Faculty of Medicine, Department of Cardiology, Clinical Hospital Centre Zemun, University of Belgrade, Vukova 9, 11080 Belgrade, Serbia.
BHF Centre for Cardiovascular Science, University of Edinburgh, Chancellors Building, Little France Crescent, Edinburgh, EH16 4SB, UK.
Eur Heart J Cardiovasc Imaging. 2021 Mar 22;22(4):367-371. doi: 10.1093/ehjci/jeaa111.
Early and late cardiovascular (CV) toxicities related to many cancer treatments may complicate the clinical course of patients, offsetting therapeutic benefits, and altering prognosis. The early detection, monitoring, and treatment of cardiotoxicity have therefore become essential parts of cancer patient care. CV imaging is a cornerstone of every cardio-oncology unit, but its use may vary across Europe because of the non-uniform availability of advanced imaging techniques and differences in the organization and logistics of cardio-oncology services. The purpose of this EACVI survey in cardio-oncology is to obtain real-world data on the current usage of cardiac imaging in cancer patients. Data from 104 centres and 35 different countries confirmed that cardiac imaging plays a pivotal role in the detection and monitoring of cardiac toxicity in oncology patients in Europe and beyond. However, it also revealed gaps between guidelines recommendations and everyday clinical practice, highlighting some of the challenges that need to be overcome in this rapidly advancing field.
早期和晚期心血管毒性与许多癌症治疗相关，可能会使患者的临床病程复杂化，抵消治疗益处，并改变预后。因此，早期发现、监测和治疗心脏毒性已成为癌症患者护理的重要组成部分。心血管影像学是每个肿瘤心脏病学中心的基石，但由于先进影像学技术的供应不均和肿瘤心脏病学服务的组织和后勤方面的差异，其在欧洲的应用可能存在差异。这项在肿瘤心脏病学领域的 EACVI 调查旨在获取有关癌症患者心脏成像当前使用情况的真实数据。来自 104 个中心和 35 个不同国家的数据证实，心脏成像在欧洲及其他地区癌症患者心脏毒性的检测和监测中发挥着关键作用。然而，它也揭示了指南建议与日常临床实践之间的差距，突出了在这个快速发展的领域中需要克服的一些挑战。
